Summary

The 7 major eosinophilic esophagitis markets reached a value of US$ 896.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7,604.7 Million by 2034, exhibiting a growth rate (CAGR) of 21.46% during 2024-2034.

The eosinophilic esophagitis market has been comprehensively analyzed in IMARC's new report titled "Eosinophilic Esophagitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Eosinophilic esophagitis refers to a chronic immune-mediated disorder that mainly affects the esophagus, which is the muscular tube connecting the throat to the stomach. This ailment is characterized by the presence of an abnormally high number of a white blood cell variant, called eosinophils, in the lining of the esophagus, leading to inflammation and damage to the tissue. The symptoms of the disease can vary from person to person but mostly include difficulty swallowing, chest pain, heartburn, regurgitation, and food impaction. Children suffering from this condition may also experience trouble eating, vomiting, abdominal pain, failure to thrive, poor growth, malnutrition, weight loss, etc. The diagnosis of eosinophilic esophagitis is typically based on a review of the patient's medical history, clinical features, and blood tests. The healthcare provider may also perform an endoscopy to examine the upper digestive tract and validate the diagnosis among patients. Additionally, a biopsy of the esophagus, which involves the removal of a small tissue sample and its examination under a microscope, is recommended.

The rising incidences of food and environmental allergies that trigger the immune response, leading to scarring and inflammation of the esophagus, are primarily driving the eosinophilic esophagitis market. Moreover, the increasing prevalence of various associated risk factors, such as family history, cold or dry climate, chronic respiratory diseases, etc., are also bolstering the market growth. Additionally, the widespread adoption of potent medications, including proton pump inhibitors and topical steroids to reduce inflammation and suppress the eosinophils, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to introduce advanced diagnostic tools that can detect early signs of the illness and help in better disease monitoring. This, in turn, is also creating a positive outlook for the market. Additionally, the growing popularity of monoclonal antibodies for treating the ailment, owing to their several benefits, including more reproducible effects than other conventional therapies and improved outcomes in patients, is expected to drive the eosinophilic esophagitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the eosinophilic esophagitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for eosinophilic esophagitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the eosinophilic esophagitis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the eosinophilic esophagitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the eosinophilic esophagitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current eosinophilic esophagitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the eosinophilic esophagitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the eosinophilic esophagitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the eosinophilic esophagitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of eosinophilic esophagitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of eosinophilic esophagitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of eosinophilic esophagitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with eosinophilic esophagitis across the seven major markets?
What is the size of the eosinophilic esophagitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of eosinophilic esophagitis?
What will be the growth rate of patients across the seven major markets?

Eosinophilic Esophagitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for eosinophilic esophagitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the eosinophilic esophagitis market?
What are the key regulatory events related to the eosinophilic esophagitis market?
What is the structure of clinical trial landscape by status related to the eosinophilic esophagitis market?
What is the structure of clinical trial landscape by phase related to the eosinophilic esophagitis market?
What is the structure of clinical trial landscape by route of administration related to the eosinophilic esophagitis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Eosinophilic Esophagitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Eosinophilic Esophagitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Eosinophilic Esophagitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Eosinophilic Esophagitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Eosinophilic Esophagitis - Unmet Needs

10 Eosinophilic Esophagitis - Key Endpoints of Treatment

11 Eosinophilic Esophagitis - Marketed Products
11.1 List of Eosinophilic Esophagitis Marketed Drugs Across the Top 7 Markets
11.1.1 Dupixent (Dupilumab) - Regeneron/Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jorveza (Budesonide orodispersible tablets) - Dr Falk Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Eosinophilic Esophagitis - Pipeline Drugs
12.1 List of Eosinophilic Esophagitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Tezepelumab - Amgen/AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cendakimab - Celgene Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 APT 1011 - Ellodi Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ESO101 - EsoCap
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Barzolvolimab - Celldex Therapeutics Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Eosinophilic Esophagitis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Eosinophilic Esophagitis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Eosinophilic Esophagitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Eosinophilic Esophagitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Eosinophilic Esophagitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Eosinophilic Esophagitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Eosinophilic Esophagitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Eosinophilic Esophagitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Eosinophilic Esophagitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Eosinophilic Esophagitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Eosinophilic Esophagitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Eosinophilic Esophagitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Eosinophilic Esophagitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Eosinophilic Esophagitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Eosinophilic Esophagitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Eosinophilic Esophagitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Eosinophilic Esophagitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Eosinophilic Esophagitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Eosinophilic Esophagitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Eosinophilic Esophagitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Eosinophilic Esophagitis - Access and Reimbursement Overview

16 Eosinophilic Esophagitis - Recent Events and Inputs From Key Opinion Leaders

17 Eosinophilic Esophagitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Eosinophilic Esophagitis Market – Strategic Recommendations

19 Appendix